We are revolutionizing drug-based cell therapy. Solution for CNS diseases such as acute regression down syndrome and Alzheimer's disease. We have a lot of in-vivo studies completed, however, we will need more funding to complete additional pre-clinical studies to move forward with IND. Min of $100K investment and goal is to raise $3M.
Unlike many companies that are working on Alzheimer's Disease treatments, we are focused on regeneration approach. This is completely different than Amyloid Beta or Tau approach that have shown little effectiveness. The original concept started out of Central Florida by renowned neuro disease researcher, Dr. Sugaya, who has over 30 plus years of experience in brain research.
The company is lead by Keiji Asada, FDA regulatory expert and Dr. Sugaya and our strategy of orphan designation through Acute Regression Down Syndrome will be a fast approval process compared to conventional drug development.
Ready to Ask For Funding for your company?
Post a Funding Request